logo
Plus   Neg
Share
Email

CVS Health Raises, Narrows 2019 Adj. EPS Guidance - Quick Facts

CVS Health Corp. (CVS) raised and narrowed its fiscal 2019 adjusted earnings per share guidance range to $6.97 to $7.05 from $6.89 to $7.00. The company also raised and narrowed adjusted operating income guidance range to $15.22 billion to $15.40 billion from $15.16 billion to $15.36 billion. Analysts polled by Thomson Reuters expect the company to report profit per share of $6.98. Analysts' estimates typically exclude special items.

For the third-quarter, adjusted earnings per share was $1.84 compared to $1.73, a year ago. On average, 24 analysts polled by Thomson Reuters expected the company to report profit per share of $1.77, for the quarter.

Third-quarter total revenues increased to $64.81 billion from $47.49 billion, prior year. Analysts expected revenue of $62.99 billion, for the quarter. Adjusted revenues increased 37.1 percent. Revenue growth was primarily driven by the impact of the Aetna Acquisition, as well as increased volume and brand name drug price inflation in both the Pharmacy Services and Retail/LTC segments.

Shares of CVS Health Corp. were up 3% in pre-market trade on Wednesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Memphis Meats, a cell based meat start-up, raised $161 million in a new round of funding from Softbank Group-led investors, in order to launch products to the market. With this, total funding exceeds $180 million. Memphis Meats intends to use the new funding to build a pilot facility for the production of cell-based meat, increase the number of employees, and to bring its products to the market. Intel Corp. (INTC), the world's biggest chipmaker, Thursday said its profit and revenues for the fourth quarter trumped Wall Street estimates. The company's shares gained nearly 7 percent driven by strong outlook for the first quarter and full year 2020. Santa Clara, California-based Intel reported... ABH Pharma, Inc. and Stocknutra.com Inc. have recalled all of its dietary supplement products pursuant to a consent decree entered by the U.S. District Court for the Eastern District of New York. The companies have recalled all dietary supplement products manufactured and sold between January 2013...
Follow RTT
>